New combo therapy shows promise for hard-to-treat prostate cancer
NCT ID NCT03503344
First seen Jan 27, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This study tested whether adding targeted radiation to a hormone-blocking drug (apalutamide) helps control prostate cancer that has stopped responding to standard hormone therapy and spread to a few spots. 26 men with castration-resistant prostate cancer took part. The main goal was to see if PSA levels became undetectable after treatment. Results help guide future treatment approaches.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.